Immune reconstitution inflammatory syndrome in HIV infected late presenters starting integrase inhibitor containing antiretroviral therapy by Wijting, I.E.A. (Ingeborg) et al.
EClinicalMedicine 17 (2019) 100210
Contents lists available at ScienceDirect
EClinicalMedicine
journal homepage: https://www.journals.elsevier.com/eclinicalmedicineResearch PaperImmune reconstitution inﬂammatory syndrome in HIV infected late
presenters starting integrase inhibitor containing antiretroviral therapy
Ingeborg E.A. Wijtinga, Ferdinand W.N.M. Witb, Casper Rokxa, Eliane M.S. Leytenc,
Selwyn H. Lowed, Kees Brinkmane, Wouter F.W. Biermanf, Marjo E.E. van Kastereng,
Anneloes M. Postmaa, Vera C.M. Bloemena, Ghariba Bouchtoubia, Andy I.M. Hoepelmanh,
Marchina E. van der Endea, Peter Reissb, Bart J.A. Rijndersa,*, on behalf of the ATHENA national
observational HIV cohort
aDepartment of Internal Medicine and Infectious Diseases, Erasmus MC, University Medical Center Rotterdam, ‘s Gravendijkwal 230, 3015 CE, Rotterdam, the Netherlands
b Stichting HIV Monitoring and Department of Global Health and Division of Infectious Diseases, Amsterdam University Medical Centers, University of Amsterdam,
Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands
c Department of Internal Medicine and Infectious Diseases, Haaglanden Medical Center, Lijnbaan 32, 2512 VH Den Haag, the Netherlands
d Department of Internal Medicine and Infectious Diseases, Maastricht University Medical Center, Debyelaan, 6229 HX Maastricht, the Netherlands
eDepartment of Internal Medicine and Infectious Diseases, OLVG, Oosterpark 9, 1091 AC Amsterdam, the Netherlands
f Department of Internal Medicine/Infectious Diseases, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, the
Netherlands
g Department of Internal Medicine and Infectious Diseases, ETZ, Hilvarenbeekse Weg 60, 5022 GC Tilburg, the Netherlands
hDepartment of Internal Medicine and Infectious Diseases, University Medical Center Utrecht, University of Utrecht, Heidelberglaan 100, 3548 CX Utrecht, the
NetherlandsA R T I C L E I N F O
Article History:
Received 19 May 2019
Revised 1 October 2019
Accepted 7 November 2019
Available online 13 December 2019* Corresponding author.
E-mail address: b.rijnders@erasmusmc.nl (B.J.A. Rijnd
https://doi.org/10.1016/j.eclinm.2019.11.003
2589-5370/© 2019 Published by Elsevier Ltd. This is an oA B S T R A C T
Background: Integrase inhibitors (INI) induce a rapid decline of HIV-RNA in plasma and CD4+ T-cell recovery
in blood. Both characteristics are also associated with immune reconstitution inﬂammatory syndrome (IRIS).
Whether the use of INI-containing combination antiretroviral therapy (cART) increases the risk of IRIS is
being questioned.
Methods: Study within the Dutch ATHENA HIV observational cohort. HIV-1 infected late presenters initiating
cART after March 2009 were included if they had <200 CD4+ T-cells per mL and were diagnosed with an
opportunistic infection. IRIS was deﬁned either according to the criteria by French et al. (IRISFRENCH) or by a
clinical IRIS diagnosis of the physician (IRISCLINICAL). The primary outcomes were the association between INI
and the occurrence of IRISFRENCH and IRISFRENCH+CLINICAL in multivariable logistic regression.
Findings: 672 patients with a median CD4+ T-cell count of 35 cells per mL were included. Treatment with INI
was independently associated with IRISFRENCH as well as IRISFRENCH+CLINICAL (OR 2¢43, 95%CI:1¢454¢07, and
OR 2¢17, 95%CI:1¢453¢25). When investigating INI separately, raltegravir (RAL) remained signiﬁcantly asso-
ciated with IRISFRENCH (OR 4¢04 (95%CI:1¢99-8¢19) as well as IRISFRENCH+CLINICAL (OR 3¢07, 95%CI:1¢66-5¢69),
while dolutegravir (DTG) became associated with IRISFRENCH+CLINICAL after it replaced RAL as preferred INI in
the cohort after 2015 (OR 4¢08, 95%CI:0¢99-16¢82, p=0¢052). Too few patients used elvitegravir to drawmean-
ingful conclusions. Steroid initiation for IRIS was more likely in those who initiated INI versus in those who
did not, but no increased hospital (re)admission or mortality rates were observed.
Interpretation: In HIV late presenters from a resource rich setting, INI based treatment initiation increased the
risk of IRIS. This was observed for RAL and DTG when being initiated as preferential INI in the presence of
speciﬁc AIDS-conditions, indicative of channeling bias. Although we controlled for all relevant measured con-
founders, we cannot exclude that the observed association is partially explained by residual confounding. INI
use was not associated with mortality nor hospitalization. Therefore, our observation is no reason to avoid
INI in late presenters.Keywords:
HIV
cART
Opportunistic infection
Integrase strand transfer inhibitor
Immune reconstitution inﬂammatory
syndromeers).
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Evidence before this study
HIV-1 infected patients initiating cART which includes an inte-
grase inhibitor (INI) experience a faster plasma HIV-RNA decay
and in most randomized studies also a faster CD4 T-cell recov-
ery compared to protease inhibitor or non-nucleoside reverse
transcriptase inhibitor containing cART. These factors have pre-
viously been associated with the development of immune
reconstitution inﬂammatory syndrome (IRIS). Thus, the use of
INI may theoretically increase the incidence of IRIS. We per-
formed a search in PubMed with the keywords ‘integrase inhib-
itor’ AND ‘immune reconstitution.’ We found 18 papers,
including one randomized clinical trial and two observational
studies. The randomized REALITY trial evaluated an efavirenz
based cART regimen with the same regimen to which raltegra-
vir was added in N =1805 HIV infected late presenters in Kenia,
Zimbabwe, Uganda and Malawi. Adding raltegravir to the cART
regimen did not increase the incidence of IRIS. In a French
observational study a total of N =2287 HIV-infected patients
were included of which N =274 started an INI based cART regi-
men. In this study an assocation between INI use and a higher
risk of IRIS was observed. However, the incidence of IRIS in this
study was much lower than previously described.
Added value of this study
In our study, we hypothesized that the initiation of INI-contain-
ing cART in HIV-1 infected late presenters is an independent risk
factor for IRIS. Our study conﬁrmed the hypothesis, but only for
the integrase inhibitor raltegravir but not for dolutegravir or
elvitegravir. Corticosteroid therapy for IRIS was administered
more often to INI users. However, the increased incidence of IRIS
did not result in more days in the hospital nor in an increase in
mortality. Although we controlled for all relevant measured con-
founders, we cannot exclude that the observed association is
partially explained by residual confounding.
Implications of the available evidence
INI based cART has become the preferred ﬁrst line cART in
resource rich settings and more recently has been postulated as
the preferred regimen in resource poorer settings as well. This
will increase the number of HIV-1 late presenters exposed to
INI based cART. Our observation warrants additional studies
and most importantly randomized studies in HIV-1 late pre-
senters to investigate whether the observated association is
real. The observation is no reason to withold INI based cART in
HIV-1 late presenters.1. Introduction
Treatment with an integrase inhibitor (INI)-containing combina-
tion antiretroviral therapy (cART) regimen is recommended as thepreferred ﬁrst-line cART in current treatment guidelines for HIV-1
infected patients [1,2]. The initiation of INI-containing cART in treat-
ment-naive patients is associated with a faster decline of plasma
HIV-RNA than when a protease inhibitor (PI) or a non-nucleoside
reverse transcriptase inhibitor (NNRTI)-containing cART regimen is
initiated. In some studies, INI are also associated with a faster recov-
ery of CD4+ T-cells (CD4 count) [35]. However, a steep decline of
HIV-RNA and a fast immune recovery are also risk factors for the
immune reconstitution inﬂammatory syndrome (IRIS) [68]. There-
fore, HIV-1 infected late presenters are at a particularly high risk for
IRIS [911].
IRIS is an excessive, pathological inﬂammatory response against
antigens of opportunistic infections (OI) [12,13]. In view of the above-
mentioned arguments, the incidence of IRIS might be higher in
patients initiating INI-containing cART than in patients starting a
non-INI-containing cART regimen. However, most of the randomized
phase III trials, comparing INI-containing cART regimens with non-
INI containing cART, were not suited to answer this question. Indeed,
by excluding patients with an active OI at the start of cART, the num-
ber of patients at risk for IRIS in these studies was very limited. In
fact, patients with a suspected OI were often explicitly excluded from
being enrolled in phase III trials [4,5]. In contrast, large prospective
observational HIV cohort studies typically include a signiﬁcant num-
ber of HIV-1 infected late presenters and can therefore be used to
determine the IRIS risk in these patients [14]. IRIS can be difﬁcult to
diagnose and is associated with signiﬁcant morbidity and (re)hospi-
talization. Occasionally IRIS can be lethal, in particular in patients
with intracranial infections. We hypothesize that the initiation of INI-
containing cART is an independent risk factor for development of IRIS
in HIV-1 infected late presenters.2. Methods
2.1. Study design and participants
This was a retrospective analysis using data from the prospective
Dutch nationwide observational HIV cohort maintained by the HIV
Monitoring Foundation (Stichting HIV Monitoring, SHM), also known
as the “AIDS Therapy Evaluation in the Netherlands” (ATHENA)
cohort [15]. The ATHENA cohort comprises all patients in care for HIV
in one of the 25 Dutch HIV treatment centers, who consented to have
their data collected in ATHENA. IRIS has not been systematically col-
lected in ATHENA. Therefore, we performed chart reviews in 22 of
the 25 centers, comprising 90% of all people in care for HIV in the
Netherlands, to retrospectively diagnose and collect information on
HIV late presenters and IRIS. The chart reviews were limited to
patients initiating ﬁrst-line cART in the INI era who were considered
at increased risk for the development of IRIS. We therefore included
antiretroviral treatment naive HIV positive adults initiating cART
included in the ATHENA cohort as of March 2009 (the date that ralte-
gravir (RAL) became available in the Netherlands) until December
2016. Furthermore, the included patients had to have (1) a CD4 count
below 200 cells per mL and (2) a diagnosis of an OI prior to or within
12 months after initiation of cART. To improve case ﬁnding of
unmasking IRIS we also included all patients for full chart review
when they fulﬁlled criterion 1 and had received corticosteroids
within 12 months after cART initiation (as a proxy for severe unmask-
ing IRIS). Finally, we included all patients who had died within 12
I.E.A. Wijting et al. / EClinicalMedicine 17 (2019) 100210 3months after initiation of cART to ensure reviewing all patients where
IRIS might have contributed to their death. Patients without clinical
data available after the start of cART were excluded. The patient ﬁles
of all patients who were identiﬁed with this strategy were reviewed
on site by one of the investigators as described below.
2.2. Study procedures
All relevant data available in the ATHENA database (e.g. demo-
graphics, use of cART, CD4 counts, plasma HIV viral loads, diagnosis
and treatment of OI, concomitant medication, hospital admissions,
mortality) were retrieved. All clinical data required to verify whether a
patient fulﬁlled the predeﬁned deﬁnitions of IRIS (see below) were col-
lected or veriﬁed on site from the individual patient ﬁles by IEAW,
AMP, VCMB and GB using a standardized case report form. If based on
the predeﬁned IRIS deﬁnitions the suspicion of a potential case of IRIS
arose, the case was discussed with IEAW and BJAR or CR until a unani-
mous decision on the presence of IRIS was made. By design, blinding
the investigators for the cART regimen was not always possible.
2.3. Deﬁnitions of IRIS
Two deﬁnitions of IRIS were used: IRIS according to the criteria
described by French et al. [16] (IRISFRENCH) and a broader clinical deﬁ-
nition (IRISCLINICAL). IRISCLINICAL included all patients with IRIS docu-
mented as the most likely diagnosis in the patient ﬁle by the treating
physician or if IRIS was mentioned in the differential diagnosis and
immunosuppressive therapy for IRIS was initiated. For a more detailed
description of the IRIS deﬁnitions see supplementary appendix, page 4
and table S1. Data on all OIs which were diagnosed before or after the
start of cART were collected. Detailed information on OI and what was
considered appropriate therapy in relation to the diagnosis of IRIS is
described in the supplementary appendix, page 4.
2.4. Objectives
The primary objective of this study was to evaluate whether the
use of INI-containing cART is an independent risk factor for a com-
bined endpoint of both types of IRIS (IRISFRENCH+CLINICAL) as well as for
IRISFRENCH. Secondary objectives were to evaluate whether the use of
INI-containing cART is associated with an increased risk of the use of
corticosteroids for IRIS, hospital (re)admission after initiation of cART
and death. Endpoints were assessed within 12 months of cART initia-
tion. The occurrence of all endpoints together up to 12 months after
cART initiation was evaluated as composite endpoint.
By initial study design, we had planned to also investigate
whether time from initiation of cART to reach a plasma viral load
below 1000 and 50 copies per mL, and time from initiation of cART to
reach a CD4 count above 100 and 200 cells per mL were independent
risk factors for IRIS, but as CD4 count and especially plasma viral
loads were not systematically measured at uniform time-points by
clinicians at the time IRIS was diagnosed, we were unable to look
into these endpoints.
2.5. Statistical analyses
The risk of IRIS was compared between the patients using INI con-
taining cART and non-INI containing cART by Kaplan Meier analysis
and by calculating odds ratios (OR) with 95% conﬁdence intervals (CI)
by univariable logistic regression analysis. We performed multivari-
able logistic regression to identify independent risk factors for IRIS.
We tested for interactions of INI-use with risk factors that may also
be associated with IRIS. Patients were censored when any of the fol-
lowing occurred: a switch from an INI to a non-INI-containing cART
regimen or vice versa, death, or loss to follow up of the patient.
Potential risk factors for IRIS that could confound the associationbetween the use of INI and risk of IRIS were investigated in the multi-
variable models. These factors were demographical, immunological
and virological parameters, cART, and OI-characteristics including
the use of corticosteroids as part of OI-treatment. A full list of these
variables can be found in the supplementary appendix, table S2. In an
attempt to adjust the analysis for confounding by indication, the ﬁnal
multivariable regression models were repeated using inverse proba-
bility of treatment weighting. The analyses were done using SAS sta-
tistical software version 9.4 (SAS Institute, Cary, NC, USA).
2.6. Ethical considerations
All patients were enrolled in the ATHENA cohort and had con-
sented to have their data used by the SHM. The study protocol was
approved by the scientiﬁc review board of the SHM.
2.7. Role of the funding source
The ATHENA cohort is maintained by SHM and supported by a
grant from the Ministry of Health, Welfare, and Sport through the
Center for Infectious Disease Control of the National Institute for Pub-
lic Health and the Environment. The corresponding author had full
access to all the data in the study and had ﬁnal responsibility for the
decision to submit for publication.
3. Results
Of 24,922 patients registered in the ATHENA-cohort by December
2016, 24,684 were adults and consented to data collection [15]. Of
them, 727 were included in the study based on the selection criteria.
A total of 55 patients was subsequently excluded for various reasons
identiﬁed during the chart review; therefore, 672 patients were
included in the analyses (Fig. 1). Of those, 155 initiated an INI-con-
taining cART-regimen and 517 initiated a cART-regimen containing a
NNRTI and/or a PI. Baseline characteristics of patients who initiated
an INI-containing (‘INI’) and a non-INI-containing (‘non-INI’) ﬁrst-
line cART-regimen are listed in Table 1. The two groups were well
balanced for most of the baseline characteristics. For obvious reasons,
patients starting an INI-containing cART entered HIV-care in later
years than patients from the non-INI group (2014 versus 2011,
p < 0¢001). In the INI-group, 60 (38¢7%), 21 (13¢6%), and 74 (47¢7%)
initiated a RAL, elvitegravir-(EVG), and dolutegravir-(DTG) containing
cART-regimen, respectively, whereas in the non-INI group a compa-
rable number of patients initiated a PI-(276/517, 53¢4%) or an NNRTI-
containing (250/517, 48¢4%) regimen (nine patients used both a PI
and a NNRTI). The baseline characteristics of the patients starting
RAL, EVG, or DTG are listed in Table 2. Differences were observed
with more female patients starting RAL than DTG, (p < 0¢001) and
patients on RAL starting cART in earlier calendar years than patients
on EVG or DTG (available in the Netherlands since 2013 and 2014
respectively, p < 0¢001).
A total of 231 OIs were diagnosed in the 155 INI users, whereas
780 OIs were diagnosed in the 517 patients in the non-INI group
(1¢49 versus 1¢51 OI per patient, respectively). The most frequently
diagnosed OIs were Pneumocystis jirovecii pneumonia (PJP), mycobac-
terial infections and Kaposi’s sarcoma (KS). For an overview of the
distribution of the use of INI and non-INI-based cART in patients diag-
nosed with various OIs commonly associated with IRIS, see Fig. 2.
Patients diagnosed with mycobacterial infections were most likely to
be treated with INI-based cART.
Eight IRIS events were excluded from the analyses because they
occurred after patients switched from INI to non-INI cART (N = 1) or
vice versa (N = 7). Data from these patients were censored at the time
of switch. During the 52 weeks of follow-up IRISFRENCH was diagnosed
in 18¢1% (28/155) of patients in the INI group, and in 8¢3% (43/517) of
patients in the non-INI group (OR 2¢43, 95%CI 1¢454¢07, p = 0¢0010).
Fig. 1. Patient disposition in the study. IRIS = immune reconstitution inﬂammatory syndrome, cART = combination antiretroviral therapy, OI = opportunistic infection,
INI = integrase strand transfer inhibitor.
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ﬁrmed”, 15.5% were classiﬁed as “probable”, with no signiﬁcant differ-
ences between the various INI- and non-INI based cART regimen
(Table 3). The overall incidence of IRIS (IRISFRENCH+CLINICAL) was 32¢3%
(50/155) and 18¢0% (93/517) respectively (OR 2¢17, 95%CI 1¢453¢25, p
= 0¢0003). 63¢6% of all IRISFRENCH+CLINICAL cases were paradoxical IRIS,
25¢2% were unmasking, and for the remaining 11¢2% this information
was unknown due to limited available data on IRIS-events (Table 3).
Patients diagnosed with nontuberculous mycobacterial infections,
cryptococcal meningitis, tuberculosis, and KS were most likely to
develop IRIS. Fig. 3 shows the distribution of IRISFRENCH and IRISCLINICAL
for the various OI. The proportion of patients initiating cART and devel-
oping IRISFRENCH or IRISCLINICAL remained stable over the entire obser-
vation period, and ﬂuctuated between 19¢9% and 24¢4% per calendar
year (Supplementary Figure S1). The multivariable logistic regression
analyses showed that the use of an INI-containing cART, and a diagno-
sis ofMycobacterium avium complex before cART initiation were inde-
pendent risk factors for both IRISFRENCH and IRISFRENCH+CLINICAL, while
no signiﬁcant associations were found for baseline plasma HIV-1 RNA,
use of corticosteroids as part of the treatment for the OI, and the time
between the start of the OI treatment and the start of cART (Table 4).
The latter was evaluated by dichotomizing the number of days
between cART initiation and OI therapy initiation as >14 days or not.
As a sensitivity analysis, a cut-off of 28 and 42 days was evaluated as
well but this did not result in a signiﬁcant association either. In the
model for the combined endpoint of IRISFRENCH+CLINICAL, also a pre-
cART diagnosis of cryptococcal meningitis, tuberculosis, and KS were
signiﬁcantly associated with an increased risk for IRIS. The pre-cART
CD4 count showed a clinically plausible borderline statistically signiﬁ-
cant association with lower IRIS risk at higher CD4 counts. Apart fromINI, none of the other drug classes or individual antiretroviral agents
were signiﬁcantly associated with IRIS although a trend was observed
for efavirenz exposure and a lower risk of IRISFRENCH+CLINICAL. No signif-
icant interactions were found between the use of INI and any of the
other risk factors tested in the models.
When we investigated the three different INI separately, only RAL
remained signiﬁcantly associated with IRISFRENCH (OR 4¢04 (95%CI
1¢998¢19) as well as IRISFRENCH+CLINICAL (OR 3¢07, 95%CI 1¢665¢69)
while no signiﬁcant associations were found between the use of DTG
and IRISFRENCH or IRISFRENCH+CLINICAL (OR 1¢78 (95%CI 0¢843¢79) and
1¢33 (95%CI 0¢722¢45)). The number of patients starting EVG was
too small (N = 21) to draw meaningful conclusions in multivariable
analyses. As there were no differences in risk of developing IRIS in
patients using PI or NNRTI, we did not further subdivide the non-INI
group in the analyses. As the observed increased incidence of IRIS
with RAL but not DTG was unexpected we repeated the ﬁnal logistic
regression models for the IRISFRENCH and IRISFRENCH+CLINICAL endpoints
using inverse probability of treatment weighting and obtained simi-
lar results, in which the association of RAL with IRIS was not attenu-
ated (data not shown). KaplanMeier analysis showed that the
timing of the IRISFRENCH and IRISFRENCH+CLINICAL events was compara-
ble for all groups (see Figs. 4 and 5) with the majority of events occur-
ring within 25 weeks after initiating cART. The increased risk of IRIS
in patients using RAL was seen with both IRISFRENCH and IRISCLINICAL,
but was most pronounced with IRISFRENCH (see Table 3). Table 3 also
shows the distribution of speciﬁc OI and clinical conditions underly-
ing the IRIS diagnoses (IRISFRENCH and IRISCLINICAL combined) in
patients using INI- and non-INI-based cART. The increased risk of IRIS
in patients using RAL compared to those using non-INI-based cART,
was seen in all OI commonly associated with IRIS which were
Table 1
Baseline characteristics of patients who initiated INI-containing cART versus patients
who initiated non-INI-containing cART. INI = INtegrase Inhibitor (containing cART),
non-INI = non-INtegrase Inhibitor (containing cART), HSX = HeteroSeXual, MSM = Men
having Sex with Men, NL = the Netherlands, RAL = Raltegravir, EVG = Elvitegravir, DTG
= Dolutegravir, CS = Chi square test, UT = Unpaired T-test, WRS = Wilcoxon Rank Sum
test, * = not applicable.
INI (N = 155) Non-INI (N = 517) p-value (test)
Male sex, N (%) 123 (79¢4) 433 (83¢8) 0¢41 (CS)
Age, mean (SD) 44 (11) 44 (11) 0¢60 (UT)
Year of HIV-diagno-
sis, median (Q1,Q3)
2014 (2011,2015) 2011 (2010,2013) <0¢0001 (WRS)
HIV-RNA at HIV-
diagnosis, log10
copies per mL,
median (Q1,Q3)
5¢5 (5¢1,6¢0) 5¢5 (5¢1,5¢8) 0¢38 (WRS)
CD4+ T-lymphocytes
at HIV-diagnosis,
cells per mL,
median (Q1,Q3)
39 (13,100) 33 (18,80) 0¢33 (WRS)
Mode of transmis-
sion, N (%)
0¢25 (CS)
HSX 58 (37¢4) 197 (38¢1)
MSM 54 (34¢8) 205 (39¢7)
Unknown 19 (12¢3) 56 (10¢8)
Other 24 (15¢5) 59 (11¢4)
Region of origin, N
(%)
0¢76 (CS)
NL 84 (54¢2) 297 (57¢5)
Europe 10 (6¢5) 40 (7¢7)
Africa 22 (14¢2) 75 (14¢5)
South America and
Caribbean
16 (10¢3) 57 (11¢0)
Other 23 (14¢8) 48 (9¢3)
Type of INI, N (%)
RAL 60 (38¢7) *
EVG 21 (13¢6) *
DTG 74 (47¢7) *
Type of cART initi-
ated, N (%)
INI + 2 NRTI 136 (87¢7) *
INI + PI + 2 NRTI 13 (8¢4) *
INI + NNRTI + 2
NRTI
6 (3¢9) *
NNRTI + 2 NRTI * 241 (46¢6)
PI + 2 NRTI * 267 (51¢6)
NNRTI + PI + 2 NRTI * 9 (1¢8)
I.E.A. Wijting et al. / EClinicalMedicine 17 (2019) 100210 5diagnosed in more than 5 patients using RAL (see Supplementary
Figure S2). The risk of developing IRIS over calendar time in patients
using INI- and non-INI-based regimens is shown in Fig. 6. The risk of
developing IRISFRENCH and IRISCLINICAL was highest in all individual
calendar years that RAL was used. From 2014 onwards DTG becameTable 2
Baseline characteristics of users of different types of INI. HSX = HeteroSeXual, MSM
Elvitegravir, DTG = Dolutegravir, CS = Chi square test, OWA = One way ANOVA, KW
RAL (N
Male sex, N (%) 41 (68
Age, mean (SD) 42 (11
Year of HIV-diagnosis, median (Q1,Q3) 2011
HIV-RNA at HIV-diagnosis, log10 copies per mL, median (Q1,Q3) 5¢6 (5
CD4+ T-lymphocytes at HIV-diagnosis, cells permL, median (Q1,Q3) 30 (10
Mode of transmission, N (%)
HSX 32 (53
MSM 15 (25
Unknown 6 (10¢
Other 7 (11¢
Region of origin, N (%)
NL 28 (46
Europe 6 (10¢
Africa 13 (21
South America and Caribbean 6 (10¢
Other 7 (11¢the most common treatment, with the number of late presenting
patients using non-INI and other INI-based regimen decreasing
sharply. In 2016 no patients initiated RAL-based cART anymore. From
2015 on, the risk of IRISFRENCH and IRISCLINICAL in patients using DTG
sharply increased. In the period 20152016 all but one IRISFRENCH
events occurred in patients using DTG. When limiting the multivari-
able logistic regression analysis of IRISFRENCH+CLINICAL to the period
20152016, use of DTG was borderline signiﬁcantly associated with
an increased risk (OR 4¢08, 95%CI 0¢9916¢82, p = 0¢052) compared to
non-INI-based cART. Patients initiating DTG-based cART before 2015
had higher pre-cART CD4 counts and CD4/8-ratios (median [IQR] 170
[56170] cells per mL and 0¢15 [0¢110¢19], respectively) compared
to those initiating DTG-based cART after 2015 (39 [20110] cells per
mL, p = 0¢053 and 0¢010 [0¢060¢12], p = 0¢029). Furthermore, the
number of opportunistic infections commonly associated with IRIS
was lower in those initiating DTG-based cART before 2015 than in
those initiating DTG-based cART after 2015: mean (SD) 0¢63 (0¢74)
versus 1¢08 (0¢85) opportunistic infections, p = 0¢13, respectively.
There were no differences in pre-cART plasma HIV-1 RNA levels and
BMI between the two groups, but statistical power was very limited.
When we compared the use of corticosteroids as therapy for
IRISFRENCH+CLINICAL, an increased use of corticosteroids for IRIS was
more likely to be observed in the INI group compared to the non-INI
group (OR 1¢56, 95% CI 0¢952¢58). The hospital (re)admission rates
after cART-initiation were comparable in both groups, being 60/155
(39%) in the INI versus 181/517 (35%) in the non-INI group (OR 1¢17,
95% CI 0¢811¢70). Similarly, the mortality rate within 12 months
was comparable at 11¢6% (18/155) and 8¢7% (45/517) in the INI and
non-INI groups respectively (OR 1¢38, 95% CI 0¢772¢46).4. Discussion
The primary goal of this study was to examine whether initiating
INI-containing cART in HIV-1 late presenters is a risk factor for IRIS.
Initiation of RAL-containing cART was identiﬁed as independent risk
factor for IRIS in multivariable logistic regression models, but
channeling bias can at least partially explain this ﬁnding. It should be
taken into consideration that the use of INI-containing cART was pre-
ferred by physicians in patients with speciﬁc OIs, a factor which we
were not able to fully correct for in the models. The observed associa-
tion of IRIS with the use of DTG was not statistically signiﬁcant during
the entire observation period, but we did observe an increased risk
for IRIS (p = 0.052) in patients starting DTG-based cART in the years
after RAL had been abandoned and had been replaced by DTG-based
cART in HIV late-presenters after clinicians became more conﬁdent in
using this new drug by 2015. Additionally, our analysis conﬁrmed= Men having Sex with Men, NL = the Netherlands, RAL = Raltegravir, EVG =
= Kruskal Wallis test.
= 60) EVG (N = 21) DTG (N = 74) p-value
¢3) 17 (81¢0) 65 (87¢8) 0¢006 (CS)
) 46 (10) 46 (12) 0¢73 (OWA)
(2009,2013) 2014 (2014,2015) 2015 (2015,2016) <0¢0001 (KW)
¢0,6¢1) 5¢6 (5¢0,5¢9) 5¢4 (5¢1,5¢8) 0¢55 (KW)
,79) 50 (20,115) 40 (12,105) 0¢34 (KW)
0¢36 (CS)
¢3) 5 (23¢8) 21 (28¢4)
¢0) 10 (47¢6) 29 (39¢2)
0) 4 (19¢0) 9 (12¢2)
7) 2 (9¢5) 15 (20¢3)
0¢80 (CS)
¢7) 11 (52¢4) 45 (60¢8)
0) 0 (0¢0) 4 (5¢4)
¢7) 3 (14¢3) 6 (8¢1)
0) 3 (14¢3) 7 (9¢5)
7) 4 (19¢0) 12 (16¢2)
Fig. 2. Use of INI- and non-INI-based cART regimens in patients diagnosed with various OI. The numbers in the stacked bars represent the percentage of patients diagnosed with a
particular OI using non-INI, DTG, RAL or EVG-based cART. The numbers on top of the stacked bars represent the total number of patients diagnosed with a particular OI. Note that
some patients were diagnosed with multiple OI. CMV = cytomegalovirus end organ disease, Toxo = cerebral toxoplasmosis, TB = (extra)pulmonary tuberculosis, MAC = non-tubercu-
lous mycobacterial infections, CM = cryptococcal meningitis, PML = progressive multifocal leukoencephalopathy, PJP = pneumocystis jirovecii pneumonia, KS = Kaposi’s sarcoma,
INI = integrase inhibitor, DTG = dolutegravir, RAL = raltegravir, EVG = elvitegravir.
Table 3
Characteristics of IRIS and clinical conditions underlying the IRIS diagnosis.
No INI, N (%) EVG, N (%) DTG, N (%) RAL, N (%)
Patients developing
IRIS
- IRISFRENCH 43 (8¢3) 1 (4¢8) 10 (13¢5) 17 (28¢3)
- IRISCLINICAL 50 (9¢7) 3 (14¢3) 8 (10¢8) 11 (18¢3)
- No IRIS 424 (82¢0) 17 (81¢0) 56 (75¢7) 32 (53¢3)
Diagnostic criteria
IRISFRENCH
- Conﬁrmed 36 (83¢8) 4 (100) 9 (90¢0) 14 (82¢4)
- Probable 7 (16¢2) 0 (0) 1 (10¢0) 3 (17¢6)
Timing of IRIS
- Paradoxical IRIS 60 (64¢5) 3 (75¢0) 9 (50¢0) 19 (67¢9)
- Unmasking IRIS 23 (24¢7) 1 (25¢0) 8 (44¢4) 4 (14¢3)
- Unknown 10 (10¢8)  1 (5¢6) 5 (17¢9)
Conditions underlying
the IRIS event
- Pneumocystis jirovecii
pneumonia
24 (25¢8) 1 (25¢0) 1 (5¢6) 3 (10¢7)
- Kaposi’s sarcoma 13 (14¢0) 1 (25¢0) 3 (16¢7) 3 (10¢7)
- Mycobacterial infec-
tions, other than TB
11 (11¢8)  6 (33¢3) 6 (21¢4)
- Tuberculosis 7 (7¢5)  1 (5¢6) 5 (17¢9)
- Cerebral toxoplasmosis 5 (5¢4)  1 (5¢6) 
- Cryptococcal
meningitis
5 (5¢4)   1 (3¢6%)
- Progressive multifocal
leukoencephalopathy
4 (4¢3)   1 (3¢6)
- Cytomegalovirus end
organ disease
3 (3¢2)  2 (11¢1) 2 (7¢1)
- Herpes zoster 2 (2¢2)   
- Non-Hodgkin
lymphoma
  1 (5¢6) 
- Histoplasmosis 1 (1¢1)   
- Fever of unknown ori-
gin, inﬂammation
12 (12¢9) 1 (25¢0) 1 (5¢6) 4 (14¢3)
- Lymphadenopathy, not
previously existing
1 (1¢1)   1 (3¢6)
- Skin conditions: der-
matitis, eczema
5 (5¢4) 1 (25¢0) 2 (11¢1) 2 (7¢1)
6 I.E.A. Wijting et al. / EClinicalMedicine 17 (2019) 100210that a pre-cART diagnosis of Mycobacterium avium complex or other
infections including tuberculosis, cryptococcal meningitis, and KS
increased the risk for IRIS. Our models did not show any evidence
that our observation was confounded by differences in patient, OI-
related, and HIV-related characteristics at the start of cART. Although
we incorporated all available measures of disease severity and pres-
ence of speciﬁc OI in our multivariable models and performed inverse
probability of treatment weighted models in an attempt to adjust for
channeling bias, it remains very well possible that channeling bias
and unmeasured confounders caused the observed associations.
Indeed, our study was non-randomized and observational. As such,
RAL may have been used preferentially in the sickest patients and/or
in patients in whom drug-drug interactions with concomitant medi-
cation had to be avoided. The possibility of channeling bias being
involved is made even more likely by our observation that when DTG
became more popular (20152016) and no new late-presenting
patients were started on RAL anymore, the risk of IRIS in patients
using DTG sharply increased, suggesting that since 2015 the patients
most at risk for IRIS are now preferentially channeled to DTG-based
cART. Patients initiating DTG-based cART after 2015 were indeed
more severely ill with lower pre-cART CD4 counts and CD4/8-ratios
and a higher number of opportunistic infections. Furthermore, the
absolute risk of IRIS in late-presenting patients starting cART has not
decreased since the use of RAL has completely stopped and DTG has
become the most often used treatment option in late-presenting
patients in the Netherlands. However, late presenting patients, who
started on DTG, developed IRIS in substantially lower proportions
compared to the risk observed in patients starting RAL-based cART
only a few years earlier. This absolute risk difference of IRIS in patients
starting RAL- and DTG-based cART may be explained by the fact that
RAL-based cART was a regimen that was only prescribed by clinicians
when drug-drug interactions needed to be avoided in late-presenting
patients with OIs, while DTG-based cART is generally preferentially
recommended by the Dutch HIV treatment guidelines, resulting in a
much larger group of late-presenting patients being started on DTG-
based cART instead of just the sickest late-presenting patients with OIs
Fig. 3. Occurrence of IRIS in patients diagnosed with various OI. The numbers in the stacked bars represent the percentage of patients diagnosed with a particular OI being diag-
nosed with IRIS. The numbers on top of the stacked bars represent the total number of patients diagnosed with a particular OI. Note that some patients were diagnosed with multi-
ple OI. CMV = cytomegalovirus end organ disease, Toxo = cerebral toxoplasmosis, TB = (extra)pulmonary tuberculosis, MAC = non-tuberculous mycobacterial infections, CM =
cryptococcal meningitis, PML = progressive multifocal leukoencephalopathy, PJP = pneumocystis jirovecii pneumonia, KS = Kaposi’s sarcoma.
Table 4
multivariable logistic regression analysis of possible risk factors for occurrence of IRIS-
FRENCH and IRISFRENCH+CLINICAL. Univ. = univariate analysis, Multiv. = multivariable analysis,
OR = Odds Ratio, INI = INtegrase Inhibitor, TB = tuberculosis, MAC = non-tuberculous
mycobacterial infections, KS = Kaposi’s sarcoma, OI = opportunistic infection.
IRISFRENCHOR (95% CI),
p-value
IRISFRENCH+CLINICAL
OR (95% CI), p-value
Use of INI 2¢46 (1¢454¢18),
0¢0009
1¢83 (1¢162¢87), 0¢009
Diagnosed with Cryptococ-
cal meningitis
2¢83 (1¢057¢66), 0¢040
Diagnosed with TB 2¢43 (1¢264¢69), 0¢008
Diagnosed with MAC 2¢96 (1¢296¢80), 0¢011 2¢89 (1¢376¢09), 0¢005
Diagnosed with KS 2¢05 (1¢153¢67), 0¢016
CD4+ T-cell count prior to
start cART (per 10 cells/
mm3 increment)
0¢96 (0¢911¢02), 0¢17 0¢96 (0¢931¢00), 0¢062
Plasma HIV RNA prior to
start cART (/log10 c/mL)
0¢97 (0¢681¢38), 0¢85 1¢10 (0¢831¢46), 0¢51
Use of corticosteroids prior
to IRIS diagnosis
0¢67 (0¢401¢14), 0¢14 1¢02 (0¢671¢54), 0¢94
No OI treatment/no AIDS
prior to start cART
Ref Ref
>2 weeks between start OI
treatment and start cART
1¢80 (0¢883¢66), 0¢11 1¢11 (0¢661¢87), 0¢71
2 weeks between start OI
treatment and start cART
1¢91 (0¢993¢67), 0¢053 0¢87 (0¢521¢45), 0¢60
Use of efavirenz 0¢62 (0¢371¢01), 0¢057
I.E.A. Wijting et al. / EClinicalMedicine 17 (2019) 100210 7and potential drugdrug-interactions. And ﬁnally, EVG-based cART
always contains the pharmacologic booster cobicistat and is hence not
a popular option in late presenting patients with OIs and co-medica-
tions with drug-drug interactions with cobicistat, possibly explaining
why IRIS is not often seen in patients using EVG.
Two recent studies have previously described an association
between INI and IRIS. First, a French multicenter observational study
investigated the incidence of IRIS requiring hospitalization in patients
initiating cART with or without an INI. In this study, baselinecharacteristics were more favorable with higher nadir CD4+ T-lympho-
cyte counts. More importantly, the study design and IRIS deﬁnition dif-
fered from our study as only IRIS-cases requiring hospitalization were
included. Second, a Greek small single center observational study
described an association of INI and IRIS as well. However, the number
of patients on any of the three INI was limited to 80. Also, patients
with any CD4 cell count at the time of cART initiation were included.
Still, despite these limitations, the authors described a signiﬁcant asso-
ciation of INI use and IRIS [17,18]. Therefore, compared with these two
studies, the strengths of our study are its larger sample size, the avail-
ability of a substantial amount of clinical data systematically registered
in the ATHENA cohort, combined with additional on-site data extrac-
tion using a detailed IRIS CRF. This allowed us to check for IRIS accord-
ing to two predeﬁned IRIS deﬁnitions, one of which also included the
clinical diagnosis of IRIS by the treating physician.
Our study has several limitations. This was an unblinded study for
the investigators, but we used several methods to avoid possible asso-
ciation bias by making the adjudication of IRIS as objective as possible
with the IRIS deﬁnitions described by French et al. Strict criteria were
used to diagnose paradoxical IRIS in a patient with KS (see methods in
the online supplement) to avoid a subjective interpretation. The
study’s observational design made us rely on the diagnostics that the
treating physician had used for a clinical IRIS diagnosis and on its doc-
umentation in the patient ﬁles. The fact that the treating physician
was aware of the type of prescribed cART to the patient may be consid-
ered a limitation as well. Indeed, in theory an increasing awareness of
a possible association between INI and IRIS over the years may have
caused clinicians to avoid INI in particular in those patients starting
cART in the more recent INI era with DTG available and speciﬁcally in
patients considered to be at very high risk for IRIS (e.g. patients with
cryptococcal meningitis or a proven or suspected mycobacterial infec-
tion). However, no such trend could be identiﬁed when we evaluated
the type of cART given to patients with a mycobacterial infection or
cryptococcal meningitis between 2009 and 2017. Actually, the oppo-
site was true; from 2009 to 2017, the use of INI progressively increased
Fig. 5. KaplanMeier analysis of occurrence of IRISFRENCH+CLINICAL in users of integrase inhibitor-containing cART versus non-integrase inhibitor-containing cART. INI = integrase
inhibitor, EVG = elvitegravir, DTG = dolutegravir, RAL = raltegravir.
Fig. 4. KaplanMeier analysis of occurrence of IRISFRENCH in users of integrase inhibitor-containing cART versus non-integrase inhibitor-containing cART. INI = integrase inhibitor,
EVG = elvitegravir, DTG = dolutegravir, RAL = raltegravir.
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Fig. 6. Risk of IRIS over calendar time is patients using INI- and non-INI-based cART. INI = integrase inhibitor, DTG = dolutegravir, RAL = raltegravir, EVG = elvitegravir.
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tococcal infections in the years 20092011 to 60% and 100% respec-
tively in the years 20152017. The lack of a plausible mechanism
behind the observed higher incidence of IRIS in patients on RAL than
on DTG is another limitation of our study.
A causal interpretation of the association between use of RAL and to
a lesser extent DTG, and the increased risk of IRIS is difﬁcult to provide
in a retrospective observational study like ours, but instead should ide-
ally be based on prospective studies in which a large number of HIV-1
late presenters are included, started on cART as soon as possible and
randomized to an INI or a non-INI containing cART regimen. This
should be possible now that the rollout of DTG containing cART in
resource-limited settings has started. The ongoing ADVANCE trial
(NCT03122262) will and the completed REALITY trial already has pro-
vided valuable data in this regard. The randomized REALITY trial useda factorial design to study the addition of RAL to NNRTI-based cART as
initial therapy and found no association between the use of RAL and
risk of IRIS. With a majority (89¢7%) on efavirenz the results of this
study are consistent with our interpretation of the observed relation-
ship between the use of RAL (and DTG) and IRIS in our study poten-
tially being caused by channeling bias [14]. While the REALITY and
ADVANCE trials recruited patients in sub-Saharan Africa, a third ran-
domized study that is about to start in Europe will provide important
insights into the matter as well. This study has IRIS as one of its prede-
ﬁned endpoints and will be the ﬁrst large study to compare a PI-based
with an INI-based cART regimen in a large number of patients newly
diagnosed with AIDS (NCT03696160, LAPTOP).
In conclusion, INI-containing cART was independently associated
with IRIS, an observation mainly driven by patients on RAL in the
period up to 2014 and in more recent years by patients on DTG. This
10 I.E.A. Wijting et al. / EClinicalMedicine 17 (2019) 100210increased incidence of IRIS was not associated with mortality nor risk
of hospital (re-) admissions and should therefore not be a reason to
avoid INI-containing cART in late presenters.
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